These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9138393)

  • 1. [Evaluation of declarations of severe adverse effects from the publication of the decree dated 13 March 1995 about the organisation of pharmacovigilance].
    Lelouet H; Morin M; Trenque T; Bidault I; Castot A; Alexandre JM
    Therapie; 1996; 51(5):555-6. PubMed ID: 9138393
    [No Abstract]   [Full Text] [Related]  

  • 2. [Good practices of publication of clinical cases of pharmacovigilance: comments, Groupe de Travail sur les Bonnes Pratiques de Publication de Cliniques en Pharmacovigilance: commentary].
    Auriche M; Bertrand P; Blay N; Danan G; Hamel JD; Imbs JL; Lagier G; Micaleff A; Moore N; Ollagnier M; Reveilleau-Richard S; Soubrié C; Weber F
    Therapie; 1997; 52(2):123-7. PubMed ID: 9231506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
    Olivier P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse drug reaction monitoring and the Internet: evaluation of the use of the Internet by French Pharmacovigilance Centres and a non-exhaustive survey of websites of interest for collecting information about adverse drug reaction.
    Morel P; Vandel B
    Therapie; 1999; 54(5):525-32. PubMed ID: 10667084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biovigilance. (Decree no 2003-1206 of December 12, 2003].
    Villeneuve P
    Rev Infirm; 2004 Mar; (99):39-40. PubMed ID: 15124496
    [No Abstract]   [Full Text] [Related]  

  • 6. [Joint program of pharmacovigilance in Quebec: comparison with France, Aquitaine and the Basque region].
    Biron P; Balency D
    Therapie; 1996; 51(5):578-81. PubMed ID: 9138400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Good practices in pharmacovigilance. Drugs for human use].
    Therapie; 1995; 50(6):547-55. PubMed ID: 8745955
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacovigilance: a case of phantom ships and Russian roulette].
    Stricker BH
    Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Regional Centers of Pharmacovigilance: a complementary source of efficiency].
    Mazé F; Bégaud B
    Therapie; 1998; 53(4):397-400. PubMed ID: 9806011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highlights of the 22nd French pharmacovigilance meeting.
    Prescrire Int; 2002 Feb; 11(57):21-3. PubMed ID: 11985373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use.
    Kunac DL; Harrison-Woolrych M; Tatley MV
    N Z Med J; 2008 Oct; 121(1283):76-89. PubMed ID: 18841188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacovigilance--a commitment of medical professional.
    Daga S
    J Indian Med Assoc; 2008 Dec; 106(12):775. PubMed ID: 19370945
    [No Abstract]   [Full Text] [Related]  

  • 13. European pharmacovigilance: an overview of pharmacovigilance inspections.
    Koster MC; van den Oetelaar AH
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):711-3. PubMed ID: 16142691
    [No Abstract]   [Full Text] [Related]  

  • 14. [Reporting drug side effects in dermatology].
    Jonville-Béra AP
    Ann Dermatol Venereol; 2001 Jan; 128(1):58. PubMed ID: 11291643
    [No Abstract]   [Full Text] [Related]  

  • 15. Getting to grips with the new European Union pharmacovigilance legislation.
    Waller P
    Pharmacoepidemiol Drug Saf; 2011 May; 20(5):544-9. PubMed ID: 21394813
    [No Abstract]   [Full Text] [Related]  

  • 16. European pharmacovigilance legislation: has it led to implementation of pharmacovigilance inspections?
    Bleumink GS; in't Veld BA; Stricker BH
    Pharmacoepidemiol Drug Saf; 2001; 10(4):339-40. PubMed ID: 11760496
    [No Abstract]   [Full Text] [Related]  

  • 17. Documentation and evaluation of adverse drug reactions (ADR)--contribution from a poison information center.
    Mey C; Hentschel H; Hippius M; Balogh A
    Int J Clin Pharmacol Ther; 2002 Mar; 40(3):102-7. PubMed ID: 11911597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paediatric pharmacovigilance.
    Prescrire Int; 2002 Dec; 11(62):183. PubMed ID: 12472099
    [No Abstract]   [Full Text] [Related]  

  • 19. [Evaluation of reports on "pregnancy and drugs" received during a period of 39 months by the Regional Pharmacovigilance Center, Lorraine (Nancy)].
    Hanesse B; Trechot P; el Kouch S; Pierfitte C; Royer R; Netter P
    Therapie; 1995; 50(5):471-2. PubMed ID: 8571291
    [No Abstract]   [Full Text] [Related]  

  • 20. [Drug observatories to make practices safer].
    Lanoue MC
    Soins; 2014 Apr; (784):40-2. PubMed ID: 24839684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.